Shots:

• Cullinan will receive $20M up front and is eligible to receive ~$211M in development- regulatory and sales-based milestone payments
• Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong- Macau and Taiwan
• CLN-081 is an orally available- small-molecule- irreversible EGFR inhibitor- which is currently in P-I/IIa dose escalation and expansion trial for NSCLC patients

 ­ Ref: GlobeNewswire | Image: Business Wire